A5108748431- Heart Failure Treatment and Management
- Cardiac pacing and defibrillation studies
- Cardiovascular Function and Risk Factors
- Pulmonary Hypertension Research and Treatments
- Cardiac Arrhythmias and Treatments
- Hemodynamic Monitoring and Therapy
- Mechanical Circulatory Support Devices
- Cardiac electrophysiology and arrhythmias
- Atrial Fibrillation Management and Outcomes
- Potassium and Related Disorders
- Cardiovascular and exercise physiology
- Blood Pressure and Hypertension Studies
- Congenital Heart Disease Studies
- Health Systems, Economic Evaluations, Quality of Life
- Medication Adherence and Compliance
- Heart Rate Variability and Autonomic Control
- Cardiac Structural Anomalies and Repair
- Pharmaceutical Practices and Patient Outcomes
- Dialysis and Renal Disease Management
- Body Composition Measurement Techniques
- Cardiac Imaging and Diagnostics
- Cardiac Arrest and Resuscitation
- Electrolyte and hormonal disorders
- Cardiac Health and Mental Health
- Electrical and Bioimpedance Tomography
Scripps Clinic
2015-2024
University of California, San Diego
2019-2024
Auerbach Associates (United States)
2024
Scripps Health
2008-2023
La Jolla Alcohol Research
2022
Scripps Institution of Oceanography
2008-2022
Scripps Green Hospital
2009-2022
Scripps Memorial Hospital
2020-2021
Abbott (United States)
2021
McMaster University
2021
Background— A treatment gap exists between heart failure (HF) guidelines and the clinical care of patients. The Registry to Improve Use Evidence-Based Heart Failure Therapies in Outpatient Setting (IMPROVE HF) prospectively tested a multidimensional practice-specific performance improvement intervention on use guideline-recommended therapies for HF outpatient cardiology practices. Methods Results— Performance data were collected random sample patients from 167 US practices at baseline,...
Previous studies suggest that management of ambulatory hemodynamics may improve outcomes in chronic heart failure. We conducted a prospective, observational, first-in-human study physician-directed patient self-management system targeting left atrial pressure.Forty patients with reduced or preserved ventricular ejection fraction and history New York Heart Association class III IV failure acute decompensation were implanted an investigational pressure monitor, readings acquired twice daily....
Background: Ambulatory hemodynamic monitoring with an implantable pulmonary artery (PA) sensor is approved for patients New York Heart Association Class III heart failure (HF) and a prior HF hospitalization (HFH) within 12 months. The objective of this study was to assess the efficacy safety PA pressure-guided therapy in routine clinical practice special focus on subgroups defined by sex, race, ejection fraction. Methods: This multi-center, prospective, open-label, observational, single-arm...
Background— Few data exist regarding contemporary care patterns for heart failure (HF) in the outpatient setting. IMPROVE HF is a prospective cohort study designed to characterize current management of patients with chronic and ejection fraction ≤35% national registry 167 US cardiology practices. Methods Results— Baseline patient characteristics on 15381 diagnosed or prior myocardial infarction left ventricular dysfunction were collected by chart abstraction. To quantify use therapies, 7...
Elevated pulmonary artery (PA) pressures in patients with heart failure are associated a high risk for hospitalization and mortality. Recent clinical trial evidence demonstrated direct relationship between lowering remotely monitored PA reduction novel implantable pressure monitoring system (CardioMEMS HF System, St. Jude Medical). This study examines changes the first 2000 US implanted general practice use.Deidentified data from remote Merlin.net (St. Medical) database were used to examine...
Left ventricular outflow tract velocity time integral (LVOT VTI) is a measure of cardiac systolic function and output. Heart failure patients with low output are known to have poor cardiovascular outcomes. Thus, extremely LVOT VTI may predict heart at highest risk for mortality. Patients were identified from single-center database. Baseline characteristics related clinical outcomes (death, LVAD) obtained 12 months. Correlation between endpoints the following variables analyzed: ejection...
Congest Heart Fail. 2011;17:248–254. ©2011 Wiley Periodicals, Inc. Clinical trial results support the hypothesis that implantable hemodynamic monitoring (IHM) systems may reduce hospitalizations among patients with chronic heart failure (HF). The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Failure (REDUCE hf ) study was a prospective, randomized, multicenter, single-blinded enrolled New York Association class II or III symptoms, an indication for...
Assessment of the quality care for outpatients with heart failure (HF) has focused on development and use process-based performance measures, supposition that these process measures are associated clinical outcomes. However, this association not been evaluated current emerging outpatient HF measures.Performance 7 (4 3 emerging) 2 summary was assessed at baseline in patients from 167 US cardiology practices prospectively followed up 24 months. Participants included 15 177 reduced left...
Background— We classified patients’ atrial fibrillation (AF), assessed its impact on biventricular pacing (BIVP%), and determined whether AF classification or BIVP% independently correlate with mortality in cardiac resynchronization therapy defibrillator patients. Methods Results— Cardiac patients were as permanent (daily mean burden ≥23 hours), persistent (≥7 consecutive days of hours/d), paroxysmal (≥1 day ≥6 no/little (all others) using device-detected during the 6 months postimplant....
Few data exist to characterize the delivery of evidence-based medical therapy for outpatients with heart failure who have received implantable cardioverter-defibrillators or cardiac resynchronization (CRT) systolic dysfunction.IMPROVE HF is a prospective study characterizing management 15 381 (left ventricular ejection fraction ≤35%) enrolled from 167 US cardiology practices. Data were abstracted dose, type, and daily frequency angiotensin-converting enzyme inhibitors, angiotensin receptor...
We report the stability, accuracy, and development history of a new left atrial pressure (LAP) sensing system in ambulatory heart failure (HF) patients. A total 84 patients with advanced HF underwent percutaneous transseptal implantation sensor. Quarterly noninvasive calibration by modified Valsalva maneuver was achieved all patients, 96.5% sessions were successful reproducibility 1.2 mmHg. Absolute sensor drift maximal after 3 months at 4.7 mmHg (95% CI, 3.2–6.2 mmHg) remained stable...
Eligible outpatients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF) frequently do not receive target doses of HF medications. The Registry to Improve the Use Evidence‐Based Heart Failure Therapies in Outpatient Setting (IMPROVE HF) evaluated effect a practice‐based performance improvement intervention on treatment LVEF ≤35%. Specific agent dose were collected at baseline 24 months for angiotensin‐converting enzyme (ACE) inhibitors/angiotensin receptor blockers...